Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...

After a series of small health issues, Becky's condition quickly deteriorated. When she rang the GP they told her to come in ...

Learn more about whether Kymera Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Sapiens International Corporation , a leading global provider of software solutions for the insurance industry, announced ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

Rhumbline Advisers lifted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 44.4% during the ...

These high-yield dividend stocks are outstanding ideas for growth and income investors now, as they hold up better during a ...

Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood ...

Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...